NCCN Guidelines® Insights - Gastrointestinal Stromal Tumors, Version 2.2014
Gastrointestinal stromal tumors (GIST) are the most common soft tissue sarcoma of the gastrointestinal tract, resulting most commonly from KIT or platelet-derived growth factor receptor α (PDGFRα)–activating mutations. These NCCN Guideline Insights highlight the important updates to the NCCN Guidelines for Soft Tissue Sarcoma specific to the management of patients with GIST experiencing disease progression while on imatinib and/or sunitinib.
This activity has been designated to meet the educational needs of physicians, nurses, and pharmacists involved in the management of patients with cancer.
Upon completion of this activity, participants will be able to:
- Integrate into professional practice the updates to NCCN Guidelines for Gastrointestinal Stromal Tumors
- Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Gastrointestinal Stromal Tumors
- 1.00 Participation
- 1.00 Nurse
- 1.00 Pharmacist
- 1.00 Physician